A Recommendation of the Cancer Moonshot Blue Ribbon Panel IOTN THE IMMUNO-ONCOLOGY TRANSLATIONAL NETWORK

Advancing Research Progress to Improve Immunotherapy and Immunoprevention

Blue Ribbon Panel’s To address research challenges in is performing preclinical studies to Recommendation: immunotherapy and 1) increase the understanding of the immunoprevention, the Cancer immune system that will improve the Create A Translational SM Science Network Devoted Moonshot Blue Ribbon Panel efficacy, durability, and safety of to Immunotherapy recommended the creation of a immunotherapies across the spectrum translational science network to of adult cancers, and to 2) design Immunotherapies leverage the ability advance immunotherapy for adult immune-based approaches to prevent of the immune system to recognize cancer patients. In response to this cancers before they occur. The IOTN tumors as “foreign” and kill them. recommendation, the ultimately aims to translate Immunoprevention approaches Immuno-Oncology Translational immuno-oncology findings into enhance immunity to prevent the Network (IOTN) was formed. This clinically effective immunotherapy development of cancer. collaborative network of researchers and immunoprevention approaches.

Despite advances in immunotherapy WHY DO WE NEED AN IMMUNOTHERAPY NETWORK? and immunoprevention that have been reported over the last decade, several • To understand complex tumor-immune system interactions research challenges need to be • To identify immunological targets expressed by tumors addressed to improve their • To determine mechanisms of effective immunotherapies effectiveness for diverse populations of cancer patients. To overcome these • To examine the biology of side effects from immunotherapy challenges, researchers need to • To develop immuno-oncology approaches to prevent cancer understand the basic mechanisms of tumor immunity and effective immuno-oncology approaches, which can lead to the successful development of preclinical immunotherapeutic and immunoprevention strategies.

U.S. Department of Health & Human Services | National Institutes of Health The Power of Collaboration and Immunology

Multidisciplinary researchers are ways to improve cancer OUR GOALS HOW WE CONTRIBUTE TO other Cancer Moonshot initiatives and working together in the IOTN immunotherapies by eliminating or THE CANCER MOONSHOT NCI programs investigating tumor consortium to improve immunotherapy reducing harmful side effects. • Increase understanding of tumor immunity and identify new targets immunity to enhance the design of The IOTN is part of the Cancer and immunoprevention strategies for successful immunotherapy and • Develop improved immunotherapy and immunoprevention strategies Moonshot, which aims to accelerate many different types of cancers. Along with these research projects, the immunoprevention strategies. • Advance cancer research by sharing data, knowledge, and resources progress in cancer research, encourage IOTN includes a Cellular collaboration, and enhance data HOW WE’RE IMPROVING Immunotherapy Data Resource (CIDR) • Mitigate harmful side effects caused by immunotherapies Further, the IOTN is sharing data, sharing. The IOTN is contributing to IMMUNOTHERAPY AND and a Data Management Resource • Accelerate immuno-oncology through collaboration knowledge, and resources with the IMMUNOPREVENTION these goals by advancing research to Center (DMRC). The CIDR is collecting broader research community to improve the effectiveness of Investigators involved in data about adult cancer patients being accelerate studies of cancer. Ultimately, prevention to the public. The achieve the IOTN goals of improving immunotherapy and Immunotherapy Research Projects of treated with cell-based the findings from the IOTN could be researchers and patient advocates the understanding of tumor-immune immunoprevention for diverse cancer the IOTN are performing preclinical immunotherapies that can be used to translated into the development of involved with the various system interactions and developing patient populations. studies to define immune interactions inform the design of future preclinical safer and more effective clinical and clinical studies. The DMRC multidisciplinary IOTN projects are successful immunotherapy and immunotherapies and the design of within tumors, identify new targets for Researchers, patient advocates, staff coordinates data sharing across the collaborating across the network to immunoprevention strategies. successful immune-based approaches immunotherapies, understand from the National institutes of Health, network, promotes outreach of IOTN to prevent cancers. mechanisms of resistance to and the IOTN are collaborating and findings and resources with the immunotherapies, and test the sharing resources to accelerate broader research community, and effectiveness of new preclinical research progress in facilitates collaborations of the immunotherapeutic approaches. immuno-oncology across the spectrum network. of cancers. Additionally, groups within “The IOTN is working The IOTN Immunoprevention Research the IOTN are working together to Patient advocates of the IOTN provide Projects are identifying targets of the identify barriers for IOTN research to extend early input from the cancer patient immune system found in pre-cancerous in different scientific areas and to successes in cancer perspective on research directions for tissues and developing early develop approaches to overcome the IOTN, contribute to the interventions, such as cancer vaccines, these barriers. immunotherapy to based on these targets to prevent development of IOTN collaborative virtually all tumor types activities, and help IOTN researchers cancer. These studies are focusing on Along with interactions within the communicate scientific findings about the prevention of high-risk adult network, the IOTN is collaborating with through improved cancers, such as colon cancer, breast immunotherapy and immuno- understanding of cancer, and ovarian cancer. the mechanisms that The Immuno-Engineering to Improve enable and limit Immunotherapy (i3) Centers of the IOTN are using bioengineering and immunotherapy. systems biology approaches to build more effective, safer, and broadly available immunotherapies for a Douglas R. Lowy, M.D. diverse adult cancer patient population. “ Acting Director National Cancer Institute IOTN researchers working on Research Projects for Mitigating Immune-Related Adverse Events are investigating IOTN Research Areas

The IOTN is studying immuno-oncology in cancers across different organs of the body. To target this spectrum of tumors, our network is integrating a wide range of preclinical approaches to understand mechanisms of tumor immunity and effective immunotherapy and immunoprevention approaches. Additionally, the IOTN is working to reduce health disparities, enhance data sharing, and encourage collaborations.

• antibody engineering • B cells • cancer vaccine • CAR T cells • cell therapy • checkpoint blockade • collaboration • combination therapy • data sharing • exosomes • genomics • health disparities research • immune evasion • immune microenvironment • immune modulators • immuno-radiotherapy • immunoprevention • immunosuppression • inflammation • lymphocyte trafficking • metabolism • mitigating adverse events • multidisciplinary research • neoantigen • NK cells • overcoming resistance • stem cell transplantation • TCR discovery • technology • translation

LEARN MORE ABOUT IOTN

Find information about collaborative IOTN research and resources: iotnmoonshot.org | cancer.gov/iotn | ˜ @IOTNmoonshot | cancer.gov/brp